Quidel (NASDAQ: QDEL) and Abaxis (NASDAQ:ABAX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.


Abaxis pays an annual dividend of $0.64 per share and has a dividend yield of 0.9%. Quidel does not pay a dividend. Abaxis pays out 59.3% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares Quidel and Abaxis’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quidel $277.74 million 5.47 -$8.16 million ($0.24) -181.75
Abaxis $227.22 million 6.86 $32.71 million $1.08 63.56

Abaxis has lower revenue, but higher earnings than Quidel. Quidel is trading at a lower price-to-earnings ratio than Abaxis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Quidel and Abaxis, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quidel 0 0 6 0 3.00
Abaxis 1 4 1 0 2.00

Quidel currently has a consensus target price of $54.20, suggesting a potential upside of 24.25%. Abaxis has a consensus target price of $56.63, suggesting a potential downside of 17.50%. Given Quidel’s stronger consensus rating and higher probable upside, equities analysts plainly believe Quidel is more favorable than Abaxis.

Institutional & Insider Ownership

92.1% of Quidel shares are owned by institutional investors. Comparatively, 99.3% of Abaxis shares are owned by institutional investors. 22.0% of Quidel shares are owned by insiders. Comparatively, 4.3% of Abaxis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Quidel has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Abaxis has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.


This table compares Quidel and Abaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quidel -2.94% -3.02% -1.23%
Abaxis 10.51% 10.09% 8.69%


Abaxis beats Quidel on 10 of the 16 factors compared between the two stocks.

Quidel Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Abaxis Company Profile

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company’s segments are the medical market and the veterinary market. The Company’s medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.